Utilising enzyme-free DNA nanotechnology, immunoMUSE® kits from Amsbio enable researchers to perform ultra-sensitive, 2-plex to 4-plex custom biomarker detection in tissue while generating same-day imaging results without species or isotype constraints.

Traditionally, tissue immunofluorescence techniques have required compromises. Researchers working with FFPE tissue, low-abundance biomarkers, and complex immune environments have typically had to choose between sensitivity, workflow complexity, and panel flexibility. Often repeated staining cycles have risked morphological damage.

The proprietary design of immunoMUSE® kits allows you to use your own validated primary antibodies to detect low abundance targets with higher sensitivity than secondary antibodies and generate results the same day in a workflow that fits easily into your lab. immunoMUSE® kits are designed for researchers who need more from multiplex staining: more flexibility, more sensitivity, and more confidence to handle challenging samples.

Fitting seamlessly into your existing immunofluorescence workflow, immunoMUSE® kits help reduce complexity while improving consistency and turnaround time. The immunoMUSE® staining protocol is efficient and simple requiring only two steps at room temperature and no extra specialised equipment. immunoMUSE® kits are proven to deliver automation ready stained-to-imaged slides in less than a single day.

Beneficially immunoMUSE® kits also preserve morphology by avoiding the need for harsh stripping or repeated staining cycles that can damage tissue integrity.

To learn more about immunoMUSE® kits please visit https://www.amsbio.com/immunomuseactivateandamplify/ or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem call platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognized for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech, and pharmaceutical markets to translate innovation from bench to bedside.